Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | 5F11-28Z CAR-T cells |
Synonyms | |
Therapy Description |
5F11-28Z CAR-T cells are T-lymphocytes engineered to express a chimeric antigen receptor (CAR) targeting TNFRSF8 (CD30) that contains CD28 hinge, transmembrane, and co-stimulatory domains, and a CD3 activation domain, which may inhibit growth of TNFRSF8 (CD30)-expressing tumor cells (PMID: 33287637). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
5F11-28Z CAR-T cells | 5F11-28Z T cells|5F11-Ts | 5F11-28Z CAR-T cells are T-lymphocytes engineered to express a chimeric antigen receptor (CAR) targeting TNFRSF8 (CD30) that contains CD28 hinge, transmembrane, and co-stimulatory domains, and a CD3 activation domain, which may inhibit growth of TNFRSF8 (CD30)-expressing tumor cells (PMID: 33287637). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03049449 | Phase I | Cyclophosphamide + Fludarabine 5F11-28Z CAR-T cells | T Cells Expressing a Fully-Human Anti-CD30 Chimeric Antigen Receptor for Treating CD30-Expressing Lymphomas | Completed | USA | 0 |